Abstract
The neuroendocrine tumors represent a challenge both for diagnosis and treatment involving many specialists during the positive diagnosis, staging, and therapy response evaluation. Over the past decades, nuclear medicine procedures have acquired a relevant role in the detection of neuroendocrine tumors (NET). This chapter describes an overview of these tumors and presents the classification and the main indications of nuclear medicine tests. The recent introduction of specific PET tracers for NET studies increased even more the nuclear diagnosis and therapeutic interest in this pathology. This chapter details the procedure with In-111 DTPA octreotide and presents clinical cases.
“As the area of light expands, so does the perimeter of darkness”
A. Einstein
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsFurther Reading
Asnacios A, Courbon F, Rochaix P et al (2008) Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expressions: new prognostic factors for malignant well-differentiated endocrine tumours. J Clin Oncol 26(6):963–970
Benn DE, Robinson BG, Clifton-Bligh RJ (2015) 15 years of paraganglioma: clinical manifestations of paraganglioma syndromes types 1–5. Endocr Relat Cancer, 22(4), T91–T103. http://doi.org/10.1530/ERC-15-0268
Bodei L, Kwekkeboom DJ, Kidd M et al (2016) Radiolabeled somatostatin analogue therapy of gastroenteropancreatic cancer. Semin Nucl Med 46(3):225–238
Bodei L, Kidd M, Paganelli G et al (2015) Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging 42(1):5–19.
Bodei L, Sundin A, Kidd M, et al (2015) The status of neuroendocrine tumor imaging: from darkness to light? Neuroendocrinology 101(1):1–17.
Bombardieri E, Ambrosini V, Aktolun C et al (2010) 111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 37:1441–1448. doi:10.1007/s00259-010-1473-6
Buchmann I, Henze M, Engelbrecht S (2007) Comparison of 68 Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 34(10):1617–1626
Forrer F, Riedweg I, Maecke HR et al (2008) Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. Q J Nucl Med Mol Imaging 52(4):334–340
Forrer F, Krenning EP, Kooij PP et al (2009) Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0), Tyr(3)]octreotate. Eur J Nucl Med Mol Imaging 36(7):1138–1146
Giammarile F, Chiti A, Lassmann M, Brans B, Flux G (2008) EANM procedure guidelines for 131I-meta iodobenzylguanidine (131I-mIBG) therapy. Eur J Nucl Med Mol Imaging 35:1039–1047. doi:10.1007/s00259-008-0715-3
Gibril F, Reynolds JC, Doppman JL et al (1996) Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med 125(1):26–34
Klimstra DS, Modlin IR, Coppola D et al (2010) The pathologic classification of neuroendocrine tumours: a review of nomenclature, grading, and staging systems. Pancreas doi:10.1097/MPA.0b013e3181ec124e
Kowalski J, Henze M, Schuhmacher J et al (2003) Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D-Phe1-Tyr3-octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumours. Mol Imaging Biol 5:42–48
Kwekkeboom DJ, Krenning EP, Bakker WH (1993) Somatostatin analogue scintigraphy in carcinoid tumours. Eur J Nucl Med 20(4):283–292
Kwekkeboom DJ, Krenning EP, Scheidhauer K et al (2009) ENETS consensus guidelines for the standards of care in neuroendocrine tumours: somatostatin receptor imaging with (111) In-pentetreotide. Neuroendocrinology 90:184–189
Modlin IM, Oberg K, Chung DC et al (2008) Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9(1):61–72, Review. PubMed PMID: 18177818
Nicolas G, Giovacchini G, Müller-Brand J et al (2011) Targeted radiotherapy with radiolabeled somatostatin analogs. Endocrinol Metab Clin N Am 40(1):187–204, Review. PubMed PMID: 21349419
Olsen JO, Pozderac RV, Hinkle G et al (1995) Somatostatin receptor imaging of neuroendocrine tumours with Indium-111 pentetreotide (Octreoscan). Semin Nucl Med 25(3):251–261
Öberg K, Knigge U, Kwekkeboom D, Perren A on behalf of the ESMO Guidelines Working Group (2012) Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23 (suppl_7): vii124-vii130
Schmidt M, Scheidhauer K, Luyken C et al (1998) Somatostatin receptor imaging in intracranial tumours. Eur J Nucl Med 25(7):675–686
Vinik A, Woltering EA, Warner RRP et al (2010) NANETS consensus guidelines for the diagnosis of neuroendocrine tumour. Pancreas doi:10.1097/MPA.0b013e3181ebaffd
Virgolini I, Ambrosini V, Bomanji BJ et al (2010) Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging 37:2004–2010
Wong KK, Cahill JM, Frey KA et al (2010) Incremental value of 111-In pentetreotide SPECT/CT fusion imaging of neuroendocrine tumours. Acad Radiol 17:291–297
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Piciu, D. (2017). Neuroendocrine Tumors (NET). In: Nuclear Endocrinology. Springer, Cham. https://doi.org/10.1007/978-3-319-56582-8_10
Download citation
DOI: https://doi.org/10.1007/978-3-319-56582-8_10
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-56581-1
Online ISBN: 978-3-319-56582-8
eBook Packages: MedicineMedicine (R0)